The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A pilot trial of hu14.18-IL2 in patients with completely resectable recurrent stage III or stage IV melanoma.
Mark R. Albertini
Research Funding - Merck Serono
Erik Ranheim
No relevant relationships to disclose
Jacquelyn A Hank
No relevant relationships to disclose
Cindy Zuleger
No relevant relationships to disclose
Thomas McFarland
No relevant relationships to disclose
Jennifer Collins
No relevant relationships to disclose
Erin Clements
No relevant relationships to disclose
Sharon M. Weber
No relevant relationships to disclose
Tracey Weigel
No relevant relationships to disclose
Heather B. Neuman
No relevant relationships to disclose
Gregory K Hartig
No relevant relationships to disclose
David Mahvi
No relevant relationships to disclose
MaryBeth Henry
No relevant relationships to disclose
Jacek Gan
No relevant relationships to disclose
Richard Yang
No relevant relationships to disclose
KyungMann Kim
No relevant relationships to disclose
Stephen Gillies
No relevant relationships to disclose
Paul M. Sondel
No relevant relationships to disclose